Your browser doesn't support javascript.
loading
Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.
Yarchoan, Mark; Agarwal, Parul; Villanueva, Augusto; Rao, Shuyun; Dawson, Laura A; Llovet, Josep M; Finn, Richard S; Groopman, John D; El-Serag, Hashem B; Monga, Satdarshan P; Wang, Xin Wei; Karin, Michael; Schwartz, Robert E; Tanabe, Kenneth K; Roberts, Lewis R; Gunaratne, Preethi H; Tsung, Allan; Brown, Kimberly A; Lawrence, Theodore S; Salem, Riad; Singal, Amit G; Kim, Amy K; Rabiee, Atoosa; Resar, Linda; Hoshida, Yujin; He, Aiwu Ruth; Ghoshal, Kalpana; Ryan, Patrick B; Jaffee, Elizabeth M; Guha, Chandan; Mishra, Lopa; Coleman, C Norman; Ahmed, Mansoor M.
Affiliation
  • Yarchoan M; Department of Oncology Gastrointestinal Cancer, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
  • Agarwal P; Department of Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Villanueva A; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Rao S; Department of Surgery, Center for Translational Medicine, George Washington University, Washington D.C.
  • Dawson LA; Department of Radiation Oncology, University of Toronto, Toronto, Ontario.
  • Llovet JM; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Finn RS; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.
  • Groopman JD; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.
  • El-Serag HB; Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Santa Monica, California.
  • Monga SP; Department of Environmental Health and Engineering, Epidemiology, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland.
  • Wang XW; Department of Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas.
  • Karin M; Department of Pathology and Medicine, and Pittsburgh Liver Research Center, University of Pittsburgh, and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Schwartz RE; Department of Human Carcinogenesis, NCI, Bethesda, Maryland.
  • Tanabe KK; Department of Pharmacology, University of California, San Diego School of Medicine, San Diego, California.
  • Roberts LR; Department of Gastroenterology and Hepatology, Sanford I. Weill Medical College of Cornell University, New York, New York.
  • Gunaratne PH; Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Tsung A; Department of Medicine, Mayo Clinic, Rochester, Minnesota.
  • Brown KA; Department of Biology and Biochemistry, University of Houston, Houston, Texas.
  • Lawrence TS; Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Salem R; Department of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, Michigan.
  • Singal AG; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
  • Kim AK; Department of Radiology, Feinberg School of Medicine, Chicago, Illinois.
  • Rabiee A; Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Resar L; Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Hoshida Y; Department of Gastroenterology and Hepatology, VA Medical Center, Washington, D.C.
  • He AR; Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Ghoshal K; Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Ryan PB; Department of Medicine and Oncology, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, D.C.
  • Jaffee EM; Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio.
  • Guha C; Janssen Research & Development, LLC, Titusville, New Jersey.
  • Mishra L; Department of Oncology Gastrointestinal Cancer, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
  • Coleman CN; Department of Radiation Oncology, Pathology and Urology, Albert Einstein College of Medicine, Bronx, New York.
  • Ahmed MM; Department of Surgery, Center for Translational Medicine, George Washington University, Washington D.C.
Cancer Res ; 79(17): 4326-4330, 2019 09 01.
Article in En | MEDLINE | ID: mdl-31481419
Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Journal: Cancer Res Year: 2019 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Journal: Cancer Res Year: 2019 Document type: Article Country of publication: United States